These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. DCVax-Brain and DC vaccines in the treatment of GBM. Wheeler CJ; Black KL Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279 [TBL] [Abstract][Full Text] [Related]
23. GBM immunotherapy: Exploring molecular and clinical frontiers. Ghosh MK; Kumar S; Begam S; Ghosh S; Basu M Life Sci; 2024 Nov; 356():123018. PubMed ID: 39214286 [TBL] [Abstract][Full Text] [Related]
24. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme. Ung N; Yang I J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553 [TBL] [Abstract][Full Text] [Related]
28. Targeting EGFRvIII for glioblastoma multiforme. Yang J; Yan J; Liu B Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003 [TBL] [Abstract][Full Text] [Related]
29. Vaccine-based immunotherapy for glioblastoma. Thomas AA; Fisher JL; Ernstoff MS; Fadul CE CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578 [TBL] [Abstract][Full Text] [Related]
31. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659 [TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for Neuro-Oncology. Majd N; Dasgupta P; de Groot J Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015 [TBL] [Abstract][Full Text] [Related]
33. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. Johanns TM; Dunn GP Cancer J; 2017; 23(2):125-130. PubMed ID: 28410300 [TBL] [Abstract][Full Text] [Related]
34. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470 [TBL] [Abstract][Full Text] [Related]
35. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. Genoud V; Migliorini D Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593 [TBL] [Abstract][Full Text] [Related]
36. Current vaccine trials in glioblastoma: a review. Xu LW; Chow KK; Lim M; Li G J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271 [TBL] [Abstract][Full Text] [Related]
37. Tumor Vaccines for Malignant Gliomas. Srinivasan VM; Ferguson SD; Lee S; Weathers SP; Kerrigan BCP; Heimberger AB Neurotherapeutics; 2017 Apr; 14(2):345-357. PubMed ID: 28389997 [TBL] [Abstract][Full Text] [Related]
38. DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE. Glavatskyi O; Khranovska N; Skachkova O; Gorbach O; Khmelnytskyi H; Shuba I; Pedachenko Y; Zemskova O; Zemskova O Exp Oncol; 2023 Dec; 45(3):282-296. PubMed ID: 38186026 [TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy in brain tumors]. De Carli E; Delion M; Rousseau A Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040 [TBL] [Abstract][Full Text] [Related]